Organovo Holdings, Inc. (ONVO), a six-year-old startup, announced a partnership with the Knight Cancer Institute at the Oregon Health & Science University (OHSU) in Portland, OR, to develop more accurate 3D cancer models that could lead to new cancer therapeutics.
Today, animal models and cancer cell lines are used to identify and test potential drug candidates, but these tools have known limitations in their ability to predict clinical outcomes. "A major challenge in oncology research today is that animal models cannot accurately represent human physiology, and cell lines do not provide information on how cells act in a three-dimensional, native architecture," said renowned cancer researcher Joe W. Gray, Ph.D., director of the OHSU Center for Spatial Systems Biomedicine (OCSSB).
Using Organovo's NovoGen MMX bioprinter the two companies want to make models of cancer and metastasis that more reliably predict the safety and effectiveness of new therapeutics. These representative human disease models have the potential to improve drug discovery and development for a number of diseases, including cancer.
"The OHSU Knight Cancer Institute is consistently on the leading edge of cancer research, delivering true therapeutic breakthroughs like Gleevec," said Keith Murphy, chairman and chief executive officer at Organovo.
OHSU Knight Cancer Institute Director Brian Druker, M.D., added, "Better research models lead to a deeper understanding of disease mechanisms and more accurate information in the preclinical drug discovery and development process. We believe new technologies, like bioprinting, are important for producing more relevant models of cancer and metastasis to ultimately support the discovery of new therapeutics."
Organovo's stock closed at $4.27 yesterday. The company's yearly revenue is only $1.2 million but the market capitalization is around $201 million.
Posted in 3D Printing Company
Maybe you also like:
- 3D printing market in Japan: 7.7 billion yen by 2015
- Are 3D printing stocks overvalued? 3D Systems, Stratasys plunge
- 3D printing company ExOne announces terms for its $75 million IPO
- China may become a major 3D printing market for Stratasys
- Stratasys and Materialise 3D printed dress hit Paris Fashion Week at Iris van Herpen show
- Stratasys appoints Medicodi and PD Dental as channel partners for dental market in Korea
- 3D Systems buys COWEB
- 3D printer company ExOne files for a $75 million IPO